You are here

Home » Content

Prostat kanseri ve kronik prostatit ilişkisi

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The mechanism and etiology of prostate cancer development has not been clearly established up to date. The discovery of prostate specific antigen (PSA) has become a cornerstone in the prostate cancer diagnosis. PSA is an important organ specific tumor marker, however, it is not cancer specific. It is well known that hystopathologic changes develop in tissues where inflammation occurs. Infection and inflammation are complex response in which several pathways play role and some of these pathways are activated during the cancer process, as well. Chronic inflammation and chronic infections play important role in carcinogenesis of various organ (such as bladder, liver, colon, esophagus and stomach) and are considered to be etiologic factors in about 20% of cancers. Epidemiologic, hystologic and genetic studies suggests that there may be a relation between common conditions such as prostatitis and prostate cancer. As a conclusion, the conditions that trigger and sustain the inflammatory process may be very important for prostatic carcinogenesis.
Bookmark/Search this post with
Abstract (Original Language): 
Bu güne kadar prostat kanseri gelişimine sebep olabilecek nedenler ve mekanizmalar bütün açıklığı ile ortaya konulamamıştır. Prostat spesifik antijen'in (PSA) keşfi prostat kanseri teşhisinde dönüm noktası olmuştur. PSA önemli bir tümör belirteci olmakla birlikte organa özgü olmasına karşın kansere özgü değildir. Vücutta meydana gelen enflamatuvar durumlarda enflamasyonun meydana geldiği yerdeki dokuda histopatolojik değişikliklerin ortaya çıktığı bilinmektedir. Enfeksiyon ve enflamasyon çok sayıda yolağın görev aldığı kompleks bir yanıt olup, bu yolakların bir kısmı kanserde de aktive olmaktadır. Kronik enflamasyon ve kronik enfeksiyon değişik organlarda (mesane, karaciğer, kolon, özofagus ve mide gibi) karsinogenezde rol almakta ve erişkinlerde görülen kanserlerin yaklaşık %20'sinde etiyolojik faktör olarak sorumlu tutulmaktadır. Yapılan epidemiyolojik, histopatolojik ve genetik araştırmalar prostatit ve prostat kanseri gibi sık görülen bu patolojiler arasında bir ilişki olabileceğini göstermektedir. Sonuçta, enflamatuvar süreci tetikleyen, idame ettiren koşullar prostatik karsinogenez açısından çok önemli olabilirler.
FULL TEXT (PDF): 
PDF icon arastirmax-prostat-kanseri-kronik-prostatit-iliskisi.pdf
  • 3
28-31
  • Turkish

REFERENCES

References: 

1. Wang MC, Valenzuela LA, Murphy GP. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-163.
2. Papsidero LD, Wang MC, Valenzuela LA. A prostate antigen in sera ofprostatic cancer patients. Cancer Res 1980;40:2428-2432.
3. Kuriyama M, Wang MC, Papsidero LD. Quantitation ofprostate-specific antigen in serum by a sensitive enzymeimmunoassay. CancerRes 1980;40:4658-4662.
4. Jemal A, Siegel R, Ward E, et al. Cancer statics, 2006. CA Cancer J Clin 2006;56:106-30.
5. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum PSA values.JUrol 1994;151(6):1571-4.
6. Akdaş A, Çevik I, Tarcan T, Turkeri L, Dalaman G, Emerk K. The role of free prostate specific antigen in the diagnosis ofprostate cancer. Brith J Urol 1997;79(6):920-923.
7. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol 2005;173(6):1969-74.
8. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stres
S.D.Ü. Tıp pak.
Derg
. 2010:17(3)/ 28-31
Ergun, prostat kanseri ve kronik prostatit
31
in human carcinogenesis. Int J Cancer 2007;121:2381-
6.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860-7.
10. De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol.
2007;25(5):398-400.
11. Wagenlehner FM, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG, Hartung R, Weidner W. The role ofinflammation and infection in the pathogenesis ofprostate carcinoma.BJUInt. 2007;100(4):733-7.
12. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256-69.
13. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, et al. Pathological and molecular mechanisms ofprostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 2004;91(3):459-77.
14. Dalton DL. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989;33(6):
465.
15. Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson GM, et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000;82(3): 718¬25.
16. Dennis LK, Dawson DV. Meta-analysis ofmeasures of sexual activity and prostate cancer. Epidemiology. 2002;13(1):72-9.
17. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology2002;60(1):78-83.
18. Platz EA, De Marzo AM. Epidemiology of inflammationandprostate cancer.JUrol. 2004;171:S36-
40
19. Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA. Gonorrhea, syphilis, clinical prostatitis, and the risk ofprostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2160-6.
20. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology.
2000;56(5):828-32.
21. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia ofthe prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 2001;158(5):1767-73.
22. Al Marhoon M. Is There a Role for Helicobacter Pylori Infection inUrological Diseases? Urol J 2008;5(3):139-
43.
23. Ferrero Doria R, Perez Flores D, Terrer Artes C, Guzman Martinez-Valls PL, Morga Egea JP, Tomas Ros M, et al. Impact ofprostatic benign hyperplasia and prostatic inflammation on the increase ofprostate
specific antigen levels. Actas Urol Esp 1997;21(2):100-
104.
24. Hochreiter WW, Duncan JL, Schaeffer AJ. Evaluation ofthe bacterial flora ofthe prostate using a 16S rRNA gene based polymerase chain reaction. J Urol 2000;163(1):127-30.
25. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Eur Urol 2008 Dec;54(6):1379-84.
26. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am JPathol 2001;159(6):2159-65.
27. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects ofprostate cancer. Lancet 2003;361(9361):955- 64.
28. Bakhle YS. COX-2 and cancer: a new approach to an oldproblem. Br J Pharmacol 2001;134(6):1137-50.
29. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470(2):
M69-78.
30. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E. Aspirin use in relation to risk ofprostate cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1108-11.
31. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. Nonsteroidal anti-inflammatory drugs and risk ofdigestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000;9(1):119-23.
32. Nelson JE, Harris RE. Inverse association ofprostate cancer and non-steroidal antiinflammatory drugs (NSAIDs): results ofacase-control study. Oncol Rep 2000;7(1): 169-70.
33. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression ofcyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42(1):73-8.
34. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy ofthe prostate, but not in prostate carcinoma. Cancer Res. 2001;61(24):8617-23.

Thank you for copying data from http://www.arastirmax.com